The properties of crystals are related to their structure and therefore they can be different for different polymorphs. For example, the pharmaceutical characteristics bioavailability and shelf life can depend on the formed polymorph and its stability. We aim to understand transitions between polymorphs that occur in the solid phase, with the ultimate goal to induce or inhibit these transitions. We apply Molecular Dynamics (MD) simulations as a computational microscope to study these processes at the molecular level. Our used model systems for polymorphic behavior of molecular crystals in a pharmaceutical context are amino-acid crystals, in particular DL-norleucine. The polymorphs of DL-norleucine consist of tightly packed hydrogen-bonded bilayers with straight side chains that are weakly bound through Van-der-Waals interactions. When DL-norleucine undergoes a polymorphic transition, the bilayers shift with respect to each other.
